Phathom Pharmaceuticals (PHAT) Stock Analysis & Winston Score

Phathom Pharmaceuticals is a specialty pharmaceutical company focused on treating digestive diseases. Its main product is Voquezna, a potassium-competitive acid blocker (PCAB) approved in the United States to treat conditions like erosive esophagitis and heartburn caused by acid reflux. The company targets patients who have not responded well to older acid-reducing drugs called proton pump inhibitors (PPIs). Phathom makes money by selling Voquezna directly to pharmacies and through specialty distributors in the US market. The company is still in its early commercial stage, which explains why it is spending more than it earns — its operating margin is negative as it invests heavily in building a sales force and raising doctor awareness. Its high gross margin of roughly 83% shows the drug itself is profitable per unit sold, but the key risk is whether Phathom can grow prescriptions fast enough to cover its costs before needing additional funding, given the competitive acid-reduction drug market dominated by cheap generic PPIs.